Book Chapter
Mak, Jeffrey Y. W., Xu, Weijun and Fairlie, David P. (2017). Thiazoles in peptides and peptidomimetics. Peptidomimetics I. (pp. 235-266) edited by William D. Lubell. Cham, Switzerland: Springer. doi: 10.1007/7081_2015_176
Journal Articles
Awad, Wael, Mayall, Jemma R., Xu, Weijun, Johansen, Matt D., Patton, Timothy, Lim, Xin Yi, Galvao, Izabela, Howson, Lauren J., Brown, Alexandra C., Haw, Tatt Jhong, Donovan, Chantal, Das, Shatarupa, Albers, Gesa J., Pai, Tsung-Yu, Hortle, Elinor, Gillis, Caitlin M., Hansbro, Nicole G., Horvat, Jay C., Liu, Ligong, Mak, Jeffrey Y.W., McCluskey, James, Fairlie, David P., Corbett, Alexandra J., Hansbro, Philip M. and Rossjohn, Jamie (2025). Cigarette smoke components modulate the MR1–MAIT axis. Journal of Experimental Medicine, 222 (2) e20240896, 1-19+. doi: 10.1084/jem.20240896
Wang, Peiqi, Hill, Timothy A., Mitchell, Justin, Fitzsimmons, Rebecca L., Xu, Weijun, Loh, Zhixuan, Suen, Jacky Y., Lim, Junxian, Iyer, Abishek and Fairlie, David P. (2022). Modifying a hydroxyl patch in glucagon-like peptide 1 produces biased agonists with unique signaling profiles. Journal of Medicinal Chemistry, 65 (17), 11759-11775. doi: 10.1021/acs.jmedchem.2c00653
Jiang, Yuhong, Lim, Junxian, Wu, Kai‐Chen, Xu, Weijun, Suen, Jacky Y. and Fairlie, David P. (2021). PAR2 induces ovarian cancer cell motility by merging three signalling pathways to transactivate EGFR. British Journal of Pharmacology, 178 (4) bph.15332, 913-932. doi: 10.1111/bph.15332
Tng, Jiahui, Lim, Junxian, Wu, Kai-Chen, Lucke, Andrew J., Xu, Weijun, Reid, Robert C. and Fairlie, David P. (2020). Achiral derivatives of hydroxamate AR-42 potently inhibit class I HDAC enzymes and cancer cell proliferation. Journal of Medicinal Chemistry, 63 (11) acs.jmedchem.0c00230, 5956-5971. doi: 10.1021/acs.jmedchem.0c00230
Awad, Wael, Ler, Geraldine J. M., Xu, Weijun, Keller, Andrew N., Mak, Jeffrey Y. W., Lim, Xin Yi, Liu, Ligong, Eckle, Sidonia B. G., Le Nours, Jérôme, McCluskey, James, Corbett, Alexandra J., Fairlie, David P. and Rossjohn, Jamie (2020). The molecular basis underpinning the potency and specificity of MAIT cell antigens. Nature Immunology, 21 (4), 400-411. doi: 10.1038/s41590-020-0616-6
Das Gupta, Kaustav, Shakespear, Melanie R., Curson, James E.B., Murthy, Ambika M.V., Iyer, Abishek, Hodson, Mark P., Ramnath, Divya, Tillu, Vikas A., von Pein, Jessica B., Reid, Robert C., Tunny, Kathryn, Hohenhaus, Daniel M., Moradi, Shayli Varasteh, Kelly, Gregory M., Kobayashi, Takumi, Gunter, Jennifer H., Stevenson, Alexander J., Xu, Weijun, Luo, Lin, Jones, Alun, Johnston, Wayne A., Blumenthal, Antje, Alexandrov, Kirill, Collins, Brett M., Stow, Jennifer L., Fairlie, David P. and Sweet, Matthew J. (2020). Class IIa histone deacetylases drive toll-like receptor-inducible glycolysis and macrophage inflammatory responses via pyruvate kinase M2. Cell Reports, 30 (8), 2712-2728.e8. doi: 10.1016/j.celrep.2020.02.007
Ler, Geraldine J. M., Xu, Weijun, Mak, Jeffrey Y. W., Liu, Ligong, Bernhardt, Paul V. and Fairlie, David P (2019). Computer modelling and synthesis of deoxy and monohydroxy analogues of a ribitylaminouracil bacterial metabolite that potently activates human T cells. Chemistry – A European Journal, 25 (68) chem.201903732, 15594-15608. doi: 10.1002/chem.201903732
Jiang, Yuhong, Yau, Mei-Kwan, Lim, Junxian, Wu, Kai-Chen, Xu, Weijun, Suen, Jacky Y and Fairlie, David P (2018). A potent antagonist of protease-activated receptor 2 that inhibits multiple signaling functions in human cancer cells. The Journal of pharmacology and experimental therapeutics, 364 (2), 246-257. doi: 10.1124/jpet.117.245027
Iyer, Abishek, Xu, Weijun, Reid, Robert C and Fairlie, David P (2018). Chemical approaches to modulating complement-mediated diseases. Journal of Medicinal Chemistry, 61 (8), 3253-3276. doi: 10.1021/acs.jmedchem.7b00882
Nielsen, Daniel S., Shepherd, Nicholas E., Xu, Weijun, Lucke, Andrew J., Stoermer, Martin J. and Fairlie, David P. (2017). Orally absorbed cyclic peptides. Chemical Reviews, 117 (12), 8094-8128. doi: 10.1021/acs.chemrev.6b00838
Chua, Ming Jang, Arnold, Megan S. J., Xu, Weijun, Lancelot, Julien, Lamotte, Suzanne, Spath, Gerald F., Prina, Eric, Pierce, Raymond J., Fairlie, David P., Skinner-Adams, Tina S. and Andrews, Katherine T. (2017). Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth. International Journal for Parasitology: Drugs and Drug Resistance, 7 (1), 42-50. doi: 10.1016/j.ijpddr.2016.12.005
Mak, Jeffrey Y. W., Xu, Weijun, Reid, Robert C., Corbett, Alexandra J., Meehan, Bronwyn S., Wang, Huimeng, Chen, Zhenjun, Rossjohn, Jamie, McCluskey, James, Liu, Ligong and Fairlie, David P. (2017). Stabilizing short-lived Schiff base derivatives of 5-aminouracils that activate mucosal-associated invariant T cells. Nature Communications, 8 (1) 14599, 14599. doi: 10.1038/ncomms14599
Suen, J.Y., Adams, M. N., Lim, J., Madala, P.K., Xu, W, Cotterell, A., He, Y., Yua, Mei-Kwan, Hooper, J. D. and Fairlie, D.P. (2017). Mapping transmembrane residues of proteinase activated recpetor 2 (PAR2) that influence ligand-modulated calcium signaling. Pharmacological Research, 117, 328-342. doi: 10.1016/j.phrs.2016.12.020
Keller, Andrew N., Eckle, Sidonia B. G., Xu, Weijun, Liu, Ligong, Hughes, Victoria A., Mak, Jeffrey Y. W., Meehan, Bronwyn S., Pediongco, Troi, Birkinshaw, Richard W., Chen, Zhenjun, Wang, Huimeng, D'Souza, Criselle, Kjer-Nielsen, Lars, Gherardin, Nicholas A., Godfrey, Dale I., Kostenko, Lyudmila, Corbett, Alexandra J., Purcell, Anthony W., Fairlie, David P., McCluskey, James and Rossjohn, Jamie (2017). Drugs and drug-like molecules can modulate the function of mucosal-associated invariant T cells. Nature Immunology, 18 (4), 402-411. doi: 10.1038/ni.3679
Plisson, Fabien, Hill, Timothy A., Mitchell, Justin M., Hoang, Huy N., de Araujo, Aline D., Xu, Weijun, Cotterell, Adam, Edmonds, David J., Stanton, Robert V., Derksen, David R., Loria, Paula M., Griffith, David A., Price, David A., Liras, Spiros and Fairlie, David P. (2017). Helixconstraints and amino acid substitution in GLP-1 increase cAMP and insulin secretion but not beta-arrestin 2 signaling. European Journal of Medicinal Chemistry, 127, 703-714. doi: 10.1016/j.ejmech.2016.10.044
Seow, Vernon, Lim, Junxian, Cotterell, Adam J., Yau, Mei-Kwan, Xu, Weijun, Lohman, Rink-Jan, Kok, W. Mei, Stoermer, Martin J., Sweet, Matthew J., Reid, Robert C., Suen, Jacky Y. and Farilie, David P. (2016). Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists. Scientific Reports, 6 (1) 24575, 24575.1-24575.12. doi: 10.1038/srep24575
Yau, Mei-Kwan, Suen, Jacky Y., Xu, Weijun, Lim, Junxian, Liu, Ligong, Adams, Mark N., He, Yaowu, Hooper, John D., Reid, Robert C. and Fairlie, David P. (2016). Potent small agonists of protease activated receptor 2. ACS Medicinal Chemistry Letters, 7 (1), 105-110. doi: 10.1021/acsmedchemlett.5b00429
Xu, Weijun, Lim, Junxian, Goh, Chai-Yeen, Suen, Jacky Y., Jiang, Yuhong, Yau, Mei-Kwan, Wu, Kai-Chen, Liu, Ligong and Fairlie, David P. (2015). Repurposing Registered Drugs as Antagonists for Protease-Activated Receptor 2. Journal of Chemical Information and Modeling, 55 (10), 2079-2084. doi: 10.1021/acs.jcim.5b00500
Perry, Samuel R., Xu, Weijun, Wirija, Anna, Lim, Junxian, Yau, Mei-Kwan, Stoermer, Martin J., Lucke, Andrew J. and Fairlie, David P. (2015). Three homology models for PAR2 derived from different templates: Application to antagonist discovery. Journal of Chemical Information And Modeling, 55 (6), 1181-1191. doi: 10.1021/acs.jcim.5b00087
Xu, Weijun, Lucke, Andrew J. and Fairlie, David P. (2015). Comparing sixteen scoring functions for predicting biological activities of ligands for protein targets. Journal of Molecular Graphics and Modelling, 57, 76-88. doi: 10.1016/j.jmgm.2015.01.009
Stoermer, Martin J., Chappell, Keith J., Liebscher, Susann, Jensen, Christina M., Gan, Chun H., Gupta, Praveer K., Xu, Wei-Jun, Young, Paul R. and Fairlie, David P. (2008). Potent cationic inhibitors of West Nile Virus NS2B/NS3 protease with serum stability, cell permeability and antiviral activity. Journal of Medicinal Chemistry, 51 (18), 5714-5721. doi: 10.1021/jm800503y